MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1093/joneph/aajag074

Медицинская библиотека · Journal of nephrology · 2026

Dapagliflozin modulates diabetic kidney disease through indirect transcriptional regulation rather than direct transcriptional reversal.

Pesce Francesco, Strizzi Camillo Tancredi, Granata Antonio, Bracaccia Maria Elena, Muzi Lina, Liakopoulos Vassilios, Grandaliano Giuseppe

СтатьяПеревод в очереди

Аннотация

BACKGROUND

Diabetic kidney disease (DKD) is the leading cause of kidney failure worldwide. While sodium-glucose co-transporter 2 inhibitors (SGLT2i) confer remarkable renoprotection, the molecular mechanisms underlying their efficacy remain incompletely understood.

METHODS

We performed an integrative cross-species transcriptomic analysis comparing dapagliflozin-modulated signatures in diabetic mice with human DKD pathophysiology. Public RNA-sequencing datasets were analyzed: GSE142025 (human kidney biopsies: advanced DKD n = 21, early DKD n = 6, controls n = 9) and GSE228727 (diabetic db/db mice ± dapagliflozin).

RESULTS

Advanced human DKD exhibited 2145 dysregulated genes (False Discovery Rate [FDR] < 0.05) enriched in fibrosis and inflammation pathways. In contrast, dapagliflozin induced a focused 13-gene signature (11 downregulated, 2 upregulated). Matched-cohort analysis revealed minimal overlap between drug and disease signatures: only 7 dapagliflozin-downregulated genes were among diabetes-upregulated genes (hypergeometric P = .542). Gene Set Enrichment Analysis confirmed no global transcriptional reversal (normalized enrichment score [NES] = -1.04, FDR q = 0.86). Despite this limited overlap, unsupervised clustering using the 13-gene signature robustly stratified human patients by disease state.

CONCLUSION

SGLT2 inhibitors do not reverse disease transcriptional programs but operate through indirect modulation of a focused gene signature largely independent of primary disease drivers. This signature provides prioritized candidates for mechanistic investigation and biomarker development in DKD.

Для цитирования: Pesce Francesco, Strizzi Camillo Tancredi, Granata Antonio, Bracaccia Maria Elena, Muzi Lina, Liakopoulos Vassilios, Grandaliano Giuseppe. Dapagliflozin modulates diabetic kidney disease through indirect transcriptional regulation rather than direct transcriptional reversal.. Journal of nephrology. 2026. DOI: 10.1093/joneph/aajag074.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.